Molecular structure of ABT-888, CAS Number: 912445-05-7
ABT-888 (CAS 912445-05-7)
See product citations (24)
Alternate Names:
ABT-888 is also known as Veliparib.
Application:
ABT-888 is a potent PARP-1 and PARP-2 inhibitor, with excellent bioavailability and blood-brain permeation for in vivo studies.
CAS Number:
912445-05-7
Purity:
≥97%
Molecular Weight:
317.22
Molecular Formula:
C13H16N4O•2HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
ABT-888 is a potent inhibitor of PARP-1 and PARP-2 (potency ≤5nM in vitro). ABT-888, also known as Veliparib, does not inhibit other NAD-binding enzymes. ABT-888 has minimal CYP450 inhibition and induction. ABT-888 shows broad spectrum of chemo- and radiopotentiation. An enantiomeric purity of ≥97% makes ABT-888 suitable for in vivo studies. ABT-888 does not show inherent cytotoxicity and shows no single agent activity in tumor models. Veliparib has excellent bioavailability and good blood-brain permeation. Veliparib increases tumor growth delay resulting from radiation and DNA-damaging agents.
ABT-888 (CAS 912445-05-7) References
- Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. | Albert, JM., et al. 2007. Clin Cancer Res. 13: 3033-42. PMID: 17505006
- A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. | Liu, SK., et al. 2008. Radiother Oncol. 88: 258-68. PMID: 18456354
- Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. | Muscal, JA., et al. 2010. Cancer Chemother Pharmacol. 65: 419-25. PMID: 19526240
- Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. | Horton, TM., et al. 2009. Mol Cancer Ther. 8: 2232-42. PMID: 19671751
- ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. | Palma, JP., et al. 2009. Clin Cancer Res. 15: 7277-90. PMID: 19934293
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. | Murai, J., et al. 2012. Cancer Res. 72: 5588-99. PMID: 23118055
- The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. | Arun, B., et al. 2015. Int J Oncol. 47: 262-8. PMID: 25975349
- The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids. | Somnay, Y., et al. 2016. Cancer Gene Ther. 23: 348-354. PMID: 27632933
- Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. | Fratangelo, F., et al. 2018. Int J Oncol. 53: 1149-1159. PMID: 29956724
- ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. | Yuan, AL., et al. 2018. PLoS One. 13: e0202860. PMID: 30153289
- Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's disease. | Kam, TI., et al. 2018. Science. 362: PMID: 30385548
- The forefront of ovarian cancer therapy: update on PARP inhibitors. | Mirza, MR., et al. 2020. Ann Oncol. 31: 1148-1159. PMID: 32569725
- Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration. | Hastings, L., et al. 2022. Brain Commun. 4: fcac042. PMID: 35282165
Inhibitor of:
BRCA2, ELOF1, Enzyme, PARP-1, PARP-12, PARP-15, PARP-2, PARP-4, Rif1, and translin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ABT-888, 1 mg | sc-202901 | 1 mg | $115.00 | |||
ABT-888, 5 mg | sc-202901A | 5 mg | $170.00 | |||
ABT-888, 25 mg | sc-202901B | 25 mg | $500.00 |